45 results on '"Bighin C"'
Search Results
2. 270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort
3. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
4. 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer
5. 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella
6. 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes
7. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
8. 226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study
9. 95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)
10. Dose-dense adjuvant chemotherapy in early breast cancer: 15–year results of the phase III Mammella InterGruppo (MIG)-1 study
11. Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab
12. A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer
13. Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study
14. The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
15. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis
16. Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study
17. Dose-dense adjuvant chemotherapy, treatment-induced amenorrhea and overall survival in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase 3 studies
18. TP53 germline mutation testing in early onset breast cancer
19. The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy
20. Concurrent versus sequential adjuvant chemo-endocrine therapy in early stage hormone receptor-positive breast cancer patients: a systematic review and meta-analysis
21. Dose-dence adjuvant chemotherapy in early breast cancer: the results of 15 years of follow-up
22. Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: a systematic review and meta-analysis of randomized studies
23. Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients
24. Correlation between treatment with aromatase inhibitors and carotid intima-media thickness, carotid stenosis and abdominal aortic diameter. A prospective cohort study
25. Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (PREgnancy and FERtility) trial
26. The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatment-related premature ovarian failure in breast cancer
27. Outcomes of hormone-responsive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC) patients (P) according to their starting first-line (1st) treatment (T): chemotherapy (CT) or hormonal therapy (HT)
28. 1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04)
29. OR30 Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (pregnancy and fertility) trial
30. HM35 Role of temporary ovarian suppression obtained with GnRH analogue in reducing premature ovarian failure induced by chemotherapy in premenopausal cancer patients: a meta-analysis of randomized studies
31. Role of Temporary Ovarian Suppression Obtained with GNRH Analog in Reducing Premature Ovarian Failure (POF) Induced By Chemotherapy in Premenopausal Cancer Patients: a Meta-Analysis of Randomized Studies
32. Fertility Preservation in Young Early Breast Cancer: Strategies and Patient Preferences
33. Fulvestrant After Failur of Adjuvant Hormonal Therapy: Multicenter Retrospective Observational Study
34. Incidence of Hepatitis B and C Infections in Early Breast Cancer Patients and Impact on Systemic Treatments
35. Letrozole withdrawal response in locally advanced breast cancer
36. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
37. Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
38. Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer
39. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score
40. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
41. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
42. Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients
43. Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer
44. Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients
45. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.